Esaxerenone: Phase III started

Daiichi began the double-blind, Japanese Phase III ESAX-HTN trial to compare 2.5 and 5 mg oral CS-3150 once daily after breakfast for 12 weeks vs. 50 mg oral eplerenone in about 930 patients. The tria...